- Enhancing the anti-tumor potential of CAR T cells for the treatment of solid tumors -

LONDON, November 13, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune Biotech, Inc., Tokyo, Japan, a biotechnology company focusing on the development of innovative cancer immunotherapies, today announced that they have entered into a license agreement whereby Autolus will have the right to develop CAR T cell therapies incorporating Noile-Immune’s PRIME (proliferation-inducing and migration-enhancing) technology secreting both IL-7 and CCL19. The PRIME technology is designed to improve proliferation and trafficking into solid tumors of both engineered CAR T cells as well as the patient’s own T cells.

Through the license agreement with Noile-Immune, Autolus has gained the right to incorporate the PRIME technology in its CAR T cell programs against a limited number of cancer targets. Autolus will make an upfront cash payment and milestone payments to Noile‑Immune, and Noile-Immune is also entitled to receive royalties on net sales of resulting products. Additional terms of the agreement were not disclosed.

“We have an emerging pipeline of CAR T cell products targeting solid tumors and are excited to add the Noile-Immune PRIME technology to our existing suite of T cell programming modules. We believe the PRIME technology will help enhance the anti-tumor potential of CAR T cells and expand our ability to design and develop transformational CAR T therapies in a variety of solid tumor indications.”

Dr. Christian Itin, chairman and chief executive officer of Autolus

“Autolus is a leader in the CAR T field, and we are very pleased that they have selected our PRIME technology for their solid tumor pipeline. This agreement provides further endorsement of our technologies, which were invented by Dr. Koji Tamada, our scientific founder. We look forward to continuing to contribute to, and develop, therapies that have the potential to transform the lives of patients.”

Hidenobu Ishizaki, M.D., Ph.D., president & chief executive officer of Noile-Immune.

About Noile-Immune

Noile-Immune Biotech, Inc., based in Tokyo, Japan, is a biotechnology company focused on the development and commercialization of novel cancer immunotherapy products with breakthrough technology to eradicate cancer cells. The company aims to discover and develop innovative cancer immunotherapies through the partnerships with experts in academia including Yamaguchi University and The National Cancer Center Japan, and deliver the best-in-class therapies to patients as well. For more information, please visit https://www.noile-immune.com/english/home/.